CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.2650
+0.0055 (2.10%)
Aug 14, 2025, 2:42 PM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
325.38M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
CytoDyn News
- 19 days ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 6 weeks ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 7 weeks ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 2 months ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 3 months ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 3 months ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 3 months ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire
- 3 months ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha